Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Thallion Pharmaceuticals Inc V.TLN

Healthcare Biotechnology


TSXV:TLN - Post by User

Thallion Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Everswanon Jul 13, 2009 5:33pm
216 Views
Post# 16134481

Tarceva getting approval

Tarceva getting approval
Last week Iressa got EU approval for lung cancer.
This week data suggests approval for Tarceva.

We want these drugs to hit the markte, as 4601 is a perfect combo compliment to them.

Cheers.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities